Abstracts tagged "Adalimumab and psoriatic arthritis"

Abstract Number: 2970 • ACR/ARHP Annual Meeting 2017
Inhibition of Radiographic Progression in Psoriatic Arthritis By Adalimumab Independent of the Control of Clinical Disease Activity
Robert B.M. Landewé¹, Christopher T. Ritchlin², Laura C Coates³, Daniel Aletaha⁴, Benoît Guérette⁵, Ying Zhang⁵, Fabiana Ganz⁶ and Maja Hojnik⁷, ¹University of Amsterdam, Amsterdam, Netherlands, ²Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ³University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie AG, Baar, Switzerland, ⁷AbbVie, Ljubljana, Slovenia
Background/Purpose : Patients (pts) with psoriatic arthritis (PsA) may experience structural damage and irreversible functional impairment if not treated appropriately. Treatment with TNF inhibitors in…
Abstract Number: 2894 • ACR/ARHP Annual Meeting 2015
The Majority of Patients with Moderate to Severe Psoriatic Arthritis Had Existing Structural Damage, Predisposing Them to Further Progression, Which Was Markedly Inhibited By Adalimumab
Pranav Sheth¹, Philip J. Mease², Yihan Li³, Fabiana Ganz⁴ and Maja Hojnik⁵, ¹Group Health Associates, Trihealth, Cincinnati, OH, ²Seattle Rheumatology Associates, Seattle, WA, ³AbbVie Inc., North Chicago, IL, ⁴Neuhofstrasse 23, AbbVie AG, Baar, Switzerland, ⁵AbbVie, Ljubljana, Slovenia
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) may experience structural damage if not appropriately treated. The purpose was to determine 1) the frequency of radiographic…